Found 27 related products for "Arun Ghosh".
Dihydroquinazoline-Derived Inhibitors for Alzheimer's Disease Treatment
Novel, high-potency dihydroquinazoline derivatives have been developed to inhibit beta-secretase, showing improved solubility and oral bioavailability for potential Alzheimer's disease treatment.
Novel Anticancer Compounds
An efficient and cost-effective synthesis method has been developed for pure, bioactive natural product antitumor compounds and structural variants for pharmaceutical and cancer treatment applications.
Discovery of Potent Anti-Mpro Inhibitors for Covid-19 Treatment
A potent alpha-ketoamide derivative is a new antiviral compound with strong in-cell activity against SARS-CoV-2.
Alpha-Ketoamide Derivative Inhibits Covid-19
Novel noncovalent functionalized bis-amide derivatives potently inhibit the SARS-CoV-2 enzyme 3CLpro, offering a promising therapeutic candidate for Covid-19 treatment and pandemic control with improved drug-like characteristics.
Discovery of Potent Protease Inhibitors for Covid-19 Treatment
A new crystallization methodology optimizes the process time and significantly reduces filtration time, offering agrochemical companies a more efficient path to achieving product purity standards.
Inhibitors of Covid protease (3CLpro) for treatment of SARS-CoV-2
A novel class of highly potent compounds inhibits a key viral protease (3CLpro) in coronaviruses like SARS-CoV-2, offering superior antiviral performance over existing emergency-authorized treatments.
Bis-Amide Inhibitors for the Treatment of SARS
Highly selective and potent inhibitors targeting nicotinamide N-methyltransferase (NNMT) offer a new therapeutic strategy for a range of diseases including cancer and metabolic disorders.
COVID-19 Antiviral Compounds
A new class of drug compounds potently inhibits the SARS-CoV-2 3CL-pro enzyme, effectively blocking viral replication for use in COVID-19 treatment and drug discovery.
3C-like Protease (3CLpro) Inhibitors for treatment of COVID-19
A highly efficient and scalable synthetic route utilizes inexpensive, optically active sugars to produce a high quantity of optically pure ligand for potent HIV/AIDS compounds.
Highly Efficient and Optically Active Synthesis of Crown-THF Ligand
A novel therapeutic strategy targets the PRMT5:MEP50 protein interaction to disrupt cancer proliferation pathways, leading to the development of selective, targeted cancer treatments with fewer side effects.
Design of New Potent Class of HIV-1 Protease Inhibitors for Treatment of HIV/AIDS
A novel cancer vaccine uses sweet corn-derived nanoparticles to deliver an immune-stimulating adjuvant and a tumor antigen, effectively overcoming resistance to traditional therapies and allowing for personalized and versatile cancer treatment.
Cancer Treatment Compound Derived from Callyspongia
A synthesized compound derived from marine sponges provides a novel macrocycle for optimizing pharmaceutical properties in various cancer treatments.
Highly Potent HIV-1 Protease Inhibitors
A new class of highly potent protease inhibitors offers an improved treatment option for multidrug-resistant HIV-1, outperforming a leading FDA-approved drug by 100 times in cell culture.
Efficient synthesis of a structure critical for producing the HIV-1 drug, Darunavir
An inexpensive and easily scalable method utilizing optically active sugars increases the efficiency and purity of bis-THF synthesis, a key component in the manufacture of the HIV-1 drug Darunavir.
Highly Potent HIV-1 Protease Inhibitors with Polycyclic-THF Ligands
Novel HIV-1 protease inhibitors with high yield synthesis and promising pharmacokinetic properties show 100-fold increased antiviral activity against drug-resistant HIV strains compared to darunavir.
Potent Dimerization Inhibitors for HIV-1 Protease
Novel protease inhibitors offer superior broad-spectrum activity against multidrug-resistant HIV variants with decreased adverse side effects and improved bioavailability, representing a significant advance in antiretroviral therapy.
Cp-THF and Tp-THF-Based Novel Protease Inhibitors
In:
A promising class of novel HIV-1 protease inhibitors has been developed, demonstrating high potency and a drug-resistance profile with the potential to outperform the current industry standard, Darunavir.
Potent HIV Protease Inhibitor Against HIV/AIDS
Novel class of potent inhibitors developed to fight emerging multidrug-resistant HIV-1 variants, offering better drug-resistant properties than current ART options.
Novel class of HIV-1 protease inhibitors with potent activity and improved pharmacological properties
[...]Protein Res. 1990, 36, 544-550.) and identified 6 compounds with inhibitory constants, Ki < 10 nM -Antiviral studies are ongoing but expected to show potent activity Advantages: -Novel class of HIV-1 protease inhibitors -Improved pharmacological properties and drug resistance properties compared to darunavir Applications: -Therapeutic treatment of HIV-1 Publications: Ghosh et al.[...]
Modified Alpha-ketoamide Derivates as anti-Mpro inhibitors for Covid-19 treatment
In:
A new class of noncovalent functionalized bis-amide inhibitors demonstrates potent antiviral properties against SARS-CoV-2, offering an improved therapeutic option for Covid-19 treatment and pandemic control.
Modified Bis-amide Derivatives as Protease inhibitors for treatment of Covid-19
Novel compounds have been developed for potent antiviral activity against SARS-CoV-2 by inhibiting the virus via a mechanism of action distinct from previous drug targets.
A Class of Exceptionally Potent HIV-1 Protease Inhibitors
A novel class of exceptionally potent HIV-1 protease inhibitors offers superior efficacy against both wild-type and multidrug resistant strains, potentially reducing required dosage for HIV therapy.
Novel Diabetes Treatment
Lead compounds that inhibit the memapsin 1 enzyme are developed to increase pancreatic beta cell mass, offering a therapeutic approach for diabetes treatment and improved glucose control.
Potent Protease Inhibitors Against HIV
Nonpeptidyl compounds demonstrate high potency and lower toxicity as strong inhibitors of HIV-1 protease enzymes, effective against multidrug resistant strains for AIDS prevention and treatment.
Multidrug-Resistant HIV-1 Protease Inhibitors
New, tightly-binding protease inhibitors demonstrate superior antiviral potency and improved drug resistance against multidrug-resistant HIV variants compared to existing treatment options.
Novel Inhibitors Against SARS-CoV-2
A novel class of compounds, chemically distinct from current FDA-approved inhibitors, potently inhibits the SARS-CoV-2 main protease (3CLpro) for use in antiviral COVID-19 treatment.
Novel Ligands for HIV-1 Protease Inhibitors
A novel class of HIV-1 protease inhibitors offers a tenfold potency increase over current treatments, effectively combating multidrug-resistant strains of HIV.